For decades, calcium signaling has been recognized as central to cellular health, yet its direct mechanistic role in driving the aging process itself has remained poorly mapped. This study reframes intracellular calcium dysregulation not merely as a symptom of aging but as an active upstream driver of senescence — a distinction with significant therapeutic implications for anyone seeking to intervene in the aging process earlier and more precisely.
The research identifies a cascade that begins when calcium homeostasis falters: elevated cytoplasmic calcium causes the protein S100A6 to accumulate outside the nucleus, where it recruits CacyBP to tag PARP1 — a critical DNA-repair enzyme — for ubiquitination and degradation. With PARP1 depleted, DNA damage accumulates and cytoplasmic chromatin fragments (CCFs) form, which activate the cGAS-STING-NF-κB inflammatory axis and trigger secretion of senescence-associated secretory phenotype (SASP) factors, the inflammatory mediators that accelerate tissue aging. Critically, this mechanism was validated in both Hutchinson-Gilford Progeria Syndrome (HGPS) patient-derived cells and naturally aging human cells, and in LmnaG609G/G609G progeroid mice. Mianserin, an approved tetracyclic antidepressant, antagonized serotonin receptors HTR2B and HTR2C to reduce intracellular calcium, suppressed the entire cascade, and significantly extended lifespan in both progeroid and naturally aging mice.
Several features elevate this finding above routine aging research. The mechanistic chain — from calcium excess to PARP1 loss to DNA damage to SASP — is unusually complete and internally coherent, spanning molecular, cellular, and whole-organism levels. The fact that an already-approved drug drives the effect accelerates translational potential considerably. That said, critical limitations deserve acknowledgment: mouse lifespan extension does not reliably translate to humans, the progeroid model is a severe accelerated-aging syndrome rather than representative of typical aging, and mianserin carries known side effects including sedation and weight gain that complicate long-term human use. Whether calcium normalization alone, versus mianserin's broader pharmacology, accounts for the benefit also warrants further study. Overall, this is a substantive, potentially paradigm-shifting contribution to the longevity field.
